Showing results (1-10 of 93) with videos related to
Sort By:
Pageof 10
Methods in Molecular Biology (Clifton, N.J.)|January 9, 2013
Flow cytometric MRD detection in selected mature B-cell malignanciesSebastian Böttcher, Matthias Ritgen, Michael KnebaBlood|October 4, 2012
Has MRD monitoring superseded other prognostic factors in adult ALL?Monika Brüggemann, Thorsten Raff, Michael KnebaSeminars in Oncology|February 1, 2012
Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principleMonika Brüggemann, Nicola Gökbuget, Michael KnebaActa Haematologica|June 5, 2004
Significance of minimal residual disease in lymphoid malignanciesMonika Brüggemann, Christiane Pott, Matthias Ritgen, et al.Hematology/Oncology Clinics of North America|April 9, 2013
The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?Sebastian Böttcher, Michael Hallek, Matthias Ritgen, et al.Molecular Diagnosis & Therapy|April 29, 2017
Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?Michaela Kotrova, Jan Trka, Michael Kneba, et al.Transfusion|July 1, 2005
Establishment and optimization of a flow cytometric method for evaluation of viability of CD34+ cells after cryopreservation and comparison with trypan blue exclusion stainingAndreas Humpe, Christian Beck, Robert Schoch, et al.Best Practice & Research. Clinical Haematology|March 6, 2003
Risk-adapted treatment according to minimal residual disease in adult ALLNicola Gökbuget, Michael Kneba, Thorsten Raff, et al.Journal of Thoracic Disease|July 5, 2013
In vitro activation of hTERT-specific T cell responses in lung cancer patients following chemotherapyBenedikt Gahn, Matthias Staudinger, Katrin Woester, et al.Plos One|June 10, 2015
High-Throughput, Amplicon-Based Sequencing of the CREBBP Gene as a Tool to Develop a Universal Platform-Independent AssayMarc W Fuellgrabe, Dietrich Herrmann, Henrik Knecht, et al.Pageof 10